Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors:
- Blanca BoludaBBBlanca Boluda
- Antonio Solana-AltabellaASAntonio Solana-Altabella
- Isabel CanoICIsabel Cano
- David Martínez-CuadrónDMDavid Martínez-Cuadrón
- Evelyn Acuña-CruzEAEvelyn Acuña-Cruz
- Laura Torres-MiñanaLTLaura Torres-Miñana
- Rebeca Rodríguez-VeigaRRRebeca Rodríguez-Veiga
- Irene Navarro-VicenteINIrene Navarro-Vicente
- David Martínez-CampuzanoDMDavid Martínez-Campuzano
- Raquel García-RuizRGRaquel García-Ruiz
- Pilar LloretPLPilar Lloret
- Pedro AsensiPAPedro Asensi
Open Access
Abstract
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed AML patients, 26 (4.6%) developed fatal cardiac events, and among 525 treated patients, 19 (3.6%) experienced fatal cardiac events (CI: 2% at 6 months; 6.7% at 9 years). Prior heart disease was associated with the development of fatal cardiac events (hazard ratio (HR) = 6.9). The CI of non-fatal cardiac events was 43.7% at 6 months and 56.9% at 9 years. Age ≥ 65 (HR = 2.2), relevant cardiac antecedents (HR = 1.4), and non-intensive chemotherapy (HR = 1.8) were associated with non-fatal cardiac events. The 9-year CI of grade 1–2 QTcF prolongation was 11.2%, grade 3 was 2.7%, and no patient had grade 4–5 events. The 9-year CI of grade 1–2 cardiac failure was 1.3%, grade 3–4 was 15%, and grade 5 was 2.1%; of grade 1–2, arrhythmia was 1.9%, grade 3–4 was 9.1%, and grade 5 was 1%. Among 285 intensive therapy patients, median overall survival decreased in those experiencing grade 3–4 cardiac events (p < 0.001). We observed a high incidence of cardiac toxicity associated with significant mortality in AML.Keywords
All Related Versions
Funding Information
- Daiichi Sankyo Inc. (2016/0158, 2019/052-1, PI18/01340, PI19/00730, FI19/00059)
- Instituto de Investigación Sanitaria La Fe (2016/0158, 2019/052-1, PI18/01340, PI19/00730, FI19/00059)
- Instituto de Salud Carlos III (2016/0158, 2019/052-1, PI18/01340, PI19/00730, FI19/00059)
This publication has 35 references indexed in Scilit:
- Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicinAnnals of Hematology, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016
- Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic TrioxideJournal of Clinical Oncology, 2014
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI: Journal of the National Cancer Institute, 2010
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignanciesAnnals of Hematology, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.Journal of Clinical Oncology, 1995